February 14, 2018 / 2:52 PM / in 4 months

BRIEF-Vertex Says Mid Stage Study Testing Pain Relief Drug Met Main Goal

Feb 14 (Reuters) - Vertex Pharmaceuticals Inc:

* VERTEX ANNOUNCES TREATMENT WITH THE NAV1.8 INHIBITOR VX-150 SHOWED SIGNIFICANT RELIEF OF ACUTE PAIN IN PHASE 2 STUDY

* VERTEX PHARMACEUTICALS - VX-150 WAS GENERALLY WELL TOLERATED AND SHOWED STATISTICALLY SIGNIFICANT RELIEF OF ACUTE PAIN COMPARED TO PLACEBO IN STUDY

* VERTEX PHARMACEUTICALS INC - VERTEX ADVANCES ADDITIONAL NAV1.8 INHIBITOR, VX-128, INTO CLINICAL DEVELOPMENT

* VERTEX PHARMACEUTICALS INC - THERE WERE NO DISCONTINUATIONS FOR ADVERSE EVENTS IN ANY ARM OF STUDY

* VERTEX PHARMACEUTICALS INC - STUDY MET ITS PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below